{"id":53335,"date":"2026-01-08T13:24:07","date_gmt":"2026-01-08T05:24:07","guid":{"rendered":"https:\/\/flcube.com\/?p=53335"},"modified":"2026-01-08T13:24:08","modified_gmt":"2026-01-08T05:24:08","slug":"immuneonco-terminates-axion-licenses-regains-global-rights-to-imm2510-and-imm27m","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53335","title":{"rendered":"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M"},"content":{"rendered":"\n<p><strong>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1541:HKG\">HKG: 1541<\/a>) announced it has <strong>terminated its License and Collaboration Agreement<\/strong> with <strong>Axion<\/strong> for <strong>IMM2510\/AXN-2510<\/strong> and <strong>IMM27M\/AXN-27M<\/strong>. The termination does <strong>not affect<\/strong> the <strong>USD\u202f35\u202fmillion<\/strong> in upfront and milestone payments already received. ImmuneOnco <strong>regains all global development and commercial rights<\/strong> outside Greater China for both assets, while Axion retains a limited license to wind down clinical activities.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-termination-summary\">Deal Termination Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Licensor<\/strong><\/td><td>ImmuneOnco Biopharmaceuticals (1541.HK)<\/td><\/tr><tr><td><strong>Licensee<\/strong><\/td><td>Axion (license terminated)<\/td><\/tr><tr><td><strong>Assets<\/strong><\/td><td>IMM2510 (palverafusp \u03b1), IMM27M (tazlestobart)<\/td><\/tr><tr><td><strong>Financial Impact<\/strong><\/td><td>USD\u202f35\u202fmillion retained; no clawback<\/td><\/tr><tr><td><strong>Rights Regained<\/strong><\/td><td>Global development and commercial rights outside Greater China<\/td><\/tr><tr><td><strong>Axion Rights<\/strong><\/td><td>Limited license for wind\u2011down of clinical development only<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-asset-profiles\">Asset Profiles<\/h2>\n\n\n\n<p><strong>IMM2510 (palverafusp \u03b1) \u2013 VEGF\/PD-L1 Bispecific<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Structure<\/strong><\/td><td>mAbTrap bispecific targeting VEGF and PD\u2011L1<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Inhibits angiogenesis + sensitizes tumors to immune response<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Solid tumors (specific cancers undisclosed)<\/td><\/tr><tr><td><strong>Competitive Edge<\/strong><\/td><td>Dual blockade of tumor growth and immune evasion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>IMM27M (tazlestobart) \u2013 Next\u2011Gen CTLA\u20114 Antibody<\/strong><\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Description<\/th><\/tr><\/thead><tbody><tr><td><strong>Structure<\/strong><\/td><td>CTLA\u20114 antibody with enhanced ADCC activity<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Potent T\u2011cell activation via CTLA\u20114 blockade + Fc\u2011mediated immune cell engagement<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Oncology (specific cancers undisclosed)<\/td><\/tr><tr><td><strong>Competitive Edge<\/strong><\/td><td>Enhanced ADCC vs. first\u2011gen CTLA\u20114 inhibitors (ipilimumab)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<p><strong>Rights Regained<\/strong>: ImmuneOnco now controls <strong>global commercialization<\/strong> outside Greater China, enabling <strong>ex\u2011China licensing deals<\/strong> or <strong>direct market entry<\/strong> in US\/EU.<\/p>\n\n\n\n<p><strong>Pipeline Value<\/strong>: Combined assets target <strong>\u00a515\u201120\u202fbillion<\/strong> global oncology market opportunity (VEGF\/PD\u2011L1 bispecifics and CTLA\u20114 next\u2011gen antibodies).<\/p>\n\n\n\n<p><strong>Financial Flexibility<\/strong>: <strong>USD\u202f35\u202fmillion<\/strong> non\u2011refundable payment provides <strong>runway for Phase\u202fII trials<\/strong> without near\u2011term dilution.<\/p>\n\n\n\n<p><strong>Next Steps<\/strong>: ImmuneOnco plans <strong>partner discussions<\/strong> for <strong>ex\u2011Greater China rights<\/strong> in <strong>H1\u202f2026<\/strong>, targeting <strong>USD\u202f200\u2011300\u202fmillion<\/strong> upfront plus milestones.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding ImmuneOnco\u2019s licensing strategy, asset development plans, and financial projections for IMM2510 and IMM27M. Actual results may differ materially due to clinical trial outcomes, competitive responses, and regulatory review timelines.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1028,229,107,28,18],"class_list":["post-53335","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-1541","tag-immuneonco-biopharmaceuticals","tag-immunotherapy","tag-multi-specific-antibodies","tag-pd-1-l1"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement with Axion for IMM2510\/AXN-2510 and IMM27M\/AXN-27M. The termination does not affect the USD\u202f35\u202fmillion in upfront and milestone payments already received. ImmuneOnco regains all global development and commercial rights outside Greater China for both assets, while Axion retains a limited license to wind down clinical activities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53335\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M\" \/>\n<meta property=\"og:description\" content=\"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement with Axion for IMM2510\/AXN-2510 and IMM27M\/AXN-27M. The termination does not affect the USD\u202f35\u202fmillion in upfront and milestone payments already received. ImmuneOnco regains all global development and commercial rights outside Greater China for both assets, while Axion retains a limited license to wind down clinical activities.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53335\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-08T05:24:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-08T05:24:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53335#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53335\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M\",\"datePublished\":\"2026-01-08T05:24:07+00:00\",\"dateModified\":\"2026-01-08T05:24:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53335\"},\"wordCount\":332,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 1541\",\"ImmuneOnco Biopharmaceuticals\",\"Immunotherapy\",\"Multi-specific antibodies\",\"PD-1\\\/L1\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53335#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53335\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53335\",\"name\":\"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-08T05:24:07+00:00\",\"dateModified\":\"2026-01-08T05:24:08+00:00\",\"description\":\"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement with Axion for IMM2510\\\/AXN-2510 and IMM27M\\\/AXN-27M. The termination does not affect the USD\u202f35\u202fmillion in upfront and milestone payments already received. ImmuneOnco regains all global development and commercial rights outside Greater China for both assets, while Axion retains a limited license to wind down clinical activities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53335#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53335\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53335#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M - Insight, China&#039;s Pharmaceutical Industry","description":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement with Axion for IMM2510\/AXN-2510 and IMM27M\/AXN-27M. The termination does not affect the USD\u202f35\u202fmillion in upfront and milestone payments already received. ImmuneOnco regains all global development and commercial rights outside Greater China for both assets, while Axion retains a limited license to wind down clinical activities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53335","og_locale":"en_US","og_type":"article","og_title":"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M","og_description":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement with Axion for IMM2510\/AXN-2510 and IMM27M\/AXN-27M. The termination does not affect the USD\u202f35\u202fmillion in upfront and milestone payments already received. ImmuneOnco regains all global development and commercial rights outside Greater China for both assets, while Axion retains a limited license to wind down clinical activities.","og_url":"https:\/\/flcube.com\/?p=53335","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-08T05:24:07+00:00","article_modified_time":"2026-01-08T05:24:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53335#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53335"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M","datePublished":"2026-01-08T05:24:07+00:00","dateModified":"2026-01-08T05:24:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53335"},"wordCount":332,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 1541","ImmuneOnco Biopharmaceuticals","Immunotherapy","Multi-specific antibodies","PD-1\/L1"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53335#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53335","url":"https:\/\/flcube.com\/?p=53335","name":"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-08T05:24:07+00:00","dateModified":"2026-01-08T05:24:08+00:00","description":"ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG: 1541) announced it has terminated its License and Collaboration Agreement with Axion for IMM2510\/AXN-2510 and IMM27M\/AXN-27M. The termination does not affect the USD\u202f35\u202fmillion in upfront and milestone payments already received. ImmuneOnco regains all global development and commercial rights outside Greater China for both assets, while Axion retains a limited license to wind down clinical activities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53335#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53335"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53335#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"ImmuneOnco Terminates Axion Licenses, Regains Global Rights to IMM2510 and IMM27M"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53335","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53335"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53335\/revisions"}],"predecessor-version":[{"id":53336,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53335\/revisions\/53336"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53335"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53335"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53335"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}